Ipsen SA's ambitions to change the management of primary biliary cholangitis (PBC) are on track after the French drugmaker bagged a speedy review from US regulators for elafibranor.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?